Common Dosage
0.25mg weekly (titrated up)
Category
Weight Loss
- Significant weight loss
- Appetite suppression
- Blood sugar regulation
Semaglutide was developed by Novo Nordisk as a next-generation GLP-1 receptor agonist. It received FDA approval in 2017 as Ozempic for type 2 diabetes management, and in 2021 as Wegovy at higher doses specifically for chronic weight management — the first anti-obesity drug approved in nearly a decade. It builds on the earlier success of liraglutide (Victoza/Saxenda) but offers superior efficacy and once-weekly dosing due to structural modifications that extend its half-life to approximately 7 days.
Semaglutide mimics the GLP-1 hormone secreted by intestinal L-cells in response to food. It activates GLP-1 receptors in the pancreas (increasing glucose-dependent insulin secretion), the brain (suppressing appetite and food reward), and the gut (slowing gastric emptying). Its 94% amino acid homology to native GLP-1 combined with a C18 fatty acid chain makes it resistant to DPP-4 degradation and albumin-bound for extended circulation.
- Chronic weight management in adults with BMI ≥30 or ≥27 with weight-related comorbidities
- Type 2 diabetes glycemic control
- Cardiovascular risk reduction — the SUSTAIN-6 trial demonstrated reduced MACE (major adverse cardiovascular events)
- Non-alcoholic steatohepatitis (NASH) — reducing liver fat accumulation
- Polycystic ovary syndrome (PCOS) — improving insulin sensitivity and hormonal balance
- Alcohol and addiction research — early data on reducing cravings via dopamine pathway modulation
STEP Trial Outcomes
The STEP 1 clinical trial (n=1961) showed 14.9% average body weight reduction over 68 weeks at 2.4mg weekly versus 2.4% placebo — a landmark result that redefined obesity pharmacotherapy. Participants without lifestyle intervention still achieved ~12% weight loss, highlighting semaglutide's potency independent of behavioral change.
Type 2 Diabetes Remission
Multiple case reports from endocrinology practices describe patients achieving HbA1c normalization and discontinuing diabetes medication after sustained semaglutide use combined with caloric reduction. The combination of weight loss and direct pancreatic beta-cell preservation appears synergistic.
Cardiovascular Risk Profile
The SELECT trial (2023) demonstrated a 20% reduction in major adverse cardiovascular events in overweight/obese non-diabetic adults, leading to an expanded FDA indication for cardiovascular risk reduction — a first for an anti-obesity medication.
- Gastrointestinal side effects (nausea, vomiting, diarrhea) are common, particularly during dose escalation — typically manageable with slow titration
- Risk of medullary thyroid carcinoma — a black box warning based on rodent data; contraindicated in patients with MTC history or MEN2
- Muscle mass loss occurs alongside fat loss; resistance training and adequate protein intake are essential to preserve lean tissue
- Weight regain upon discontinuation is common without lifestyle changes — long-term use may be necessary
- Pancreatitis risk exists; contraindicated in those with history of pancreatitis
- Compounded versions from research peptide suppliers lack pharmaceutical-grade quality controls — dosing accuracy and sterility vary significantly
- Nausea
- Vomiting
- Diarrhea
- Fatigue